THE ROLE OF HUMAN PXR IN ANTI-TUBERCULOSIS DRUG-INDUCED LIVER INJURY

$211,735P20FY2011RRNIH

University Of Kansas Medical Center, Kansas City KS

Investigators

Linked publications & trials

Paper 38810120 Paper 38782768 Paper 38588852 Paper 37930118 Paper 37792503 Paper 37021787 Paper 36824917 Paper 36778348 Paper 35850385 Paper 35093590 Paper 35006629 Paper 34055653 Paper 33691903 Paper 33350342 Paper 33162398 Paper 32892153 Paper 32681035 Paper 32460011 Paper 32045647 Paper 31831621 Paper 31353905 Paper 30670473 Paper 30520062 Paper 30289596 Paper 30236171 Paper 30134762 Paper 29871716 Paper 29862868 Paper 29769197 Paper 29669937 Paper 29654721 Paper 29540258 Paper 29325178 Paper 29023917 Paper 28986474 Paper 28915934 Paper 28844948 Paper 28770701 Paper 28652407 Paper 28330868 Paper 28234577 Paper 28199845 Paper 28163822 Paper 27891514 Paper 27889601 Paper 27881673 Paper 27773698 Paper 27744120 Paper 27639429 Paper 27616656 Paper 27562556 Paper 27491879 Paper 27429052 Paper 27325701 Paper 27168224 Paper 27153767 Paper 27151938 Paper 27151180 Paper 27130888 Paper 27125733 Paper 27042213 Paper 27002509 Paper 26946532 Paper 26919968 Paper 26769846 Paper 26751492 Paper 26739624 Paper 26722668 Paper 26655101 Paper 26631581 Paper 26561740 Paper 26522885 Paper 26501336 Paper 26479335 Paper 26461121 Paper 26431796 Paper 26355817 Paper 26272158 Paper 26233910 Paper 26233906 Paper 26221041 Paper 26186639 Paper 26176423 Paper 26167291 Paper 26159696 Paper 26159260 Paper 26120557 Paper 26111001 Paper 26055554 Paper 26001962 Paper 25869248 Paper 25865938 Paper 25858113 Paper 25818599 Paper 25805502 Paper 25797999 Paper 25752611 Paper 25743375 Paper 25701738 Paper 25700366

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Drug-induced liver injury is a major safety issue in anti-tuberculosis chemotherapy. The objective of this project is to investigate the mechanisms of liver injury associated with rifampicin and isoniazid co-therapy and to develop novel strategies to manage rifampicin and isoniazid induced liver injury. By using pregnane X receptor (PXR)-humanized mice, our preliminary studies identified that human PXR is essential in rifampicin and isoniazid induced liver injury. Our central hypothesis is that rifampicin-mediated human PXR activation disturbs the metabolism of isoniazid and bile acids, and these metabolic disorders result in the liver injury caused by rifampicin and isoniazid co-therapy. In order to test our hypothesis, we will utilize the genetically engineered mouse models (Pxr-null, PXR-humanized, and Cyp3a-null mice) and the LC-MS-based metabolomic approach to pursue the following specific aims: (1). Determine the importance of Cyp3a in rifampicin and isoniazid induced liver injury. (2). Define the effects of rifampicin-mediated PXR activation on isoniazid metabolism and disposition, and determine the mechanism of rifampicin-boosted isoniazid toxicity. (3). Define the effect of rifampicin and isoniazid co-treatment on bile acid metabolism, and determine its contribution in rifampicin and isoniazid induced cholestatic injury. This work is innovative in that human PXR is identified as an essential mediator of rifampicin and isoniazid induced liver injury. Successful completion of this project will greatly enhance our knowledge on rifampicin and isoniazid induced liver injury which will be applied towards predicting, preventing, and treating the liver injury caused by rifampicin and isoniazid co-therapy.

View original record on NIH RePORTER →